| Name | Title | Contact Details |
|---|---|---|
Joel Mathews |
Director biomarker assay research and assay development | Profile |
Fernanda Hubner |
Assistant Director, Supply Chain | Profile |
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
Noxxon Pharma AG is a Germany-based biotechnology company with focus on cancer treatment. The Company develops drugs under the trademark Spiegelmer, which target the tumor microenvironment. Spiegelmers can be manufactured chemically and are a variant o...
Serán Bioscience is a contract development and manufacturing organization (CDMO) that provides drug development services to the pharmaceutical industry, including chemistry, formulation, spray drying, dosage form, analytical, and GMP manufacturing serv...
Great Lakes Drug Development is a Brighton, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.